PTC Therapeutics Inc
NASDAQ:PTCT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.15
52.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
PTC Therapeutics Inc
PTC Therapeutics Inc
Net Issuance of Common Stock
PTC Therapeutics Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
Net Issuance of Common Stock
$9.7m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-22%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Issuance of Common Stock
-$782m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Issuance of Common Stock
-$243.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PTC Therapeutics Inc
Glance View
Nestled in the heart of the biotechnology sector, PTC Therapeutics Inc. has carved a distinctive niche by foregrounding innovative genetic approaches to combat rare diseases. Founded in 1998, the company harnesses the power of science and technology to address unmet medical needs, focusing primarily on disorders originating from genetic mutations that disrupt cellular systems. At its core, PTC leverages its expertise in the discovery and development of small molecule drugs and gene therapies, an endeavor propelled by its proprietary technology platforms such as SmRT (suppressor of nonsense mutations readthrough) and dystrophin restoration technologies. These platforms enable PTC to target and modify specific gene expressions, offering potential treatments for conditions such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), which have historically eluded effective therapies. The company’s revenue generation pivots on two key streams: product sales and strategic collaborations. By marketing its FDA-approved therapies like Translarna and Emflaza for rare genetic disorders, PTC secures a steady flow of income that underscores its sustainable business model. Additionally, PTC forms strategic alliances and collaborative agreements with pharmaceutical giants, fostering a vibrant environment of shared knowledge and resources. These partnerships not only bolster its research and development capabilities but also offer potential milestone payments and royalties, further strengthening its financial portfolio. In this symbiotic landscape, PTC Therapeutics continues to navigate the complexities of biotech development, striving to transform the challenges of rare diseases into treatment opportunities, thereby weaving innovation into the very fabric of business efficacy.
See Also
What is PTC Therapeutics Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
9.7m
USD
Based on the financial report for Sep 30, 2024, PTC Therapeutics Inc's Net Issuance of Common Stock amounts to 9.7m USD.
What is PTC Therapeutics Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
-22%
Over the last year, the Net Issuance of Common Stock growth was -88%. The average annual Net Issuance of Common Stock growth rates for PTC Therapeutics Inc have been -45% over the past three years , -51% over the past five years , and -22% over the past ten years .
You don't have any saved screeners yet
